Longitudinal Assessment of Cytomegalovirus (CMV)–Specific Immune Responses in Liver Transplant Recipients at High Risk for Late CMV Disease
1Laboratory of Vaccine Research and 2Department of Biostatistics, Division of Information Sciences, Beckman Research Institute of the City of Hope, City of Hope Comprehensive Cancer Center, Duarte, California; 3University of Washington Medical Center, Seattle
Cytomegalovirus (CMV)–seronegative recipients (R−) of a liver transplant from CMV-positive donors (D+) are at high risk for developing late CMV disease after discontinuation of antiviral prophylaxis. Levels of viremia and CMV-specific interferon (IFN)–γ–producing CD4+ and IFN-γ–producing CD8+ T cell responses were prospectively measured from discontinuation of antiviral prophylaxis until 1 year after transplantation in 17 consecutive D+/R− patients. CMV loads of >1000 copies/mL were strongly associated with CMV disease in the 6 symptomatic patients. Despite immunosuppression, broadly diverse T cells specific for CMV lysate or peptide libraries spanning pp65 and immediate early (IE) 1 immunodominant CMV antigens developed in all patients. A vigorous CD8+ T cell response to pp65 and IE1 antigens characterized the D+/R− cohort. Unexpectedly, none of these responses were predictive of CMV disease or viremia. No significant lymphopenia or functional impairment of CMV-specific T cells was detected in the symptomatic patients, whose morbidity was resolved after antiviral treatment while measurable CMV immunity was maintained during the 1-year observation period.
Received 15 June 2006; accepted 29 August 2006; electronically published 22 January 2007.
Cited by
Online publication date: 1-Nov-2008.
CrossRef
Online publication date: 1-Jun-2008.
CrossRef
Online publication date: 1-Mar-2008.
CrossRef
Online publication date: 1-Feb-2008.
Online publication date: 1-Jan-2008.
Online publication date: 1-Sep-2007.
CrossRef
Online publication date: 1-Sep-2007.
CrossRef
Online publication date: 1-Mar-2007.
-
Potential conflicts of interest: none reported.
Financial support: These studies have been partially supported by grants from the National Cancer Institute (NCI; grants RO1-CA77544 and PO1-CA30206, Project III) and a subcontract from AI52065 to D.J.D. The City of Hope Comprehensive Cancer Center is supported by the NCI (grant CA33572). The Laboratory of Vaccine Research is partially supported by the Edwin and Bea Wolfe Charitable Foundation. Support for the City of Hope General Clinical Research Center (GCRC; satellite of the University of Southern California GCRC) is provided by the National Institutes of Health (grant MO1-RR0043-38).
-
(See the editorial commentary by Boeckh and Riddell, on pages 615–7.)
-
aC.L.R. and A.P.L. contributed equally to this work and should be considered co–first authors.







